Sandoz’s pegfilgrastim MAA accepted by the EMA
Sandoz announced this week that the Marketing Authorization Application (MAA) for its biosimilar to Amgen’s EU-licensed Neulasta (pegfilgrastim) has been accepted by the European Medicines Agency (EMA). Read More »